Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST. The ...
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.
Madrigal Pharmaceuticals is relocating to a larger West Conshy headquarters as sales surge and its MASH treatment drives ...
Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...
Preview this article 1 min Madrigal Pharmaceuticals is moving to a new 54,000-square-foot headquarters as its workforce nears ...
Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...
Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in ...
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...
Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...
This discovery might leave a bad taste in your mouth. A new study found that a popular low-calorie sweetener commonly used in sugar-free gum, candies and diet-friendly baked goods may increase your ...
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback